Ignite Creation Date:
2025-12-25 @ 2:47 AM
Ignite Modification Date:
2025-12-31 @ 4:12 AM
Study NCT ID:
NCT06000033
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-08-21
First Post:
2023-08-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer
Sponsor:
Qilu Hospital of Shandong University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-08-10
Start Date Type:
ESTIMATED
Primary Completion Date:
2024-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-08-14
First Submit QC Date:
None
Study First Post Date:
2023-08-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-08-14
Last Update Post Date:
2023-08-21
Last Update Post Date Type:
ACTUAL